Key result
At 30 μg/ml, DOX-ZnO-NFs demonstrated a cell survival rate of 72.53% compared to 13.8% with bare DOX, indicating reduced systemic toxicity.
Why the study?
Doxorubicin induces cardiotoxicity, hepatotoxicity, and nephrotoxicity via oxidative stress and apoptosis, motivating investigation into whether protective zinc oxide in DOX-loaded zinc oxide nanoflowers could reduce toxicity.
Does loading doxorubicin into zinc oxide nanoflowers reduce drug-induced toxicity in HeLa cells and Wistar rats compared to bare doxorubicin?
Does loading doxorubicin into zinc oxide nanoflowers reduce drug-induced toxicity in HeLa cells and Wistar rats compared to bare doxorubicin?
Absolute Event Rate: 72.53% vs 13.8%
Loading doxorubicin into zinc oxide nanoflowers significantly reduces its systemic toxicity, including cardiotoxicity, in preclinical models.
ZnO-NFs should not change DOX management; leaves open whether nanoflower delivery reduces cardiotoxicity in patients.
Doxorubicin (DOX) induces cardiotoxicity, hepatotoxicity and nephrotoxicity , through multiplicity of mechanisms involving the production of free radicals causing oxidative stress and apoptosis. Zinc oxide (ZnO) nanomaterials , besides biocompatibility and biodegradability, also show the protective effect on cells and organs. The current study aspires to delve into the protective effects of ZnO in DOX-loaded ZnO nanoflowers (DOX-ZnO-NFs). Comparative in-vitro toxicities of DOX, blank zinc oxide nanoflowers (ZnO-NFs) and DOX-ZnO-NFs were examined against in-vitro normal Henrietta Lacks (HeLa) cell line and in-vivo in the Wistar rats . The change in body weight, hematological parameters and biochemical biomarkers of heart, kidney and liver and histopathology of tissues were examined at 24 h and after 14 days post dosing of the test moieties. DOX-ZnO-NFs portrayed biocompatibility and safety in the HeLa cells and the kidneys, liver and heart of Wistar rats. At 30 μg/ml, DOX-ZnO-NFs showed 72.53 ± 0.39% cell survival rate , relative to 80.59 ± 0.99% by ZnO-NFs and 13.8 ± 0.22%, by DOX. DOX-ZnO-NFs and ZnO-NFs caused slight change in organ's weight, minimum haemolysis, little effect on liver and kidney enzymes , improved activity of antioxidant enzymes and maintained tissues' architecture relative to the bare DOX. The drug-free ZnO-NFs with the maximum safety supported the protective effect of ZnO and, thus DOX-ZnO-NFs surmounted the DOX-induced systemic toxicity.
No takes yet. Share an insight, caveat, or question.
Its licence doesn't allow us to show a copy here.
Ijaz et al. (2023) studied Doxorubicin-induced toxicity. Doxorubicin-loaded zinc oxide nanoflowers (DOX-ZnO-NFs) vs. Bare doxorubicin (DOX) and blank zinc oxide nanoflowers (ZnO-NFs) was evaluated on Cell survival rate. At 30 μg/ml, DOX-ZnO-NFs demonstrated a cell survival rate of 72.53% compared to 13.8% with bare DOX, indicating reduced systemic toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: